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Abstract. In this study, the efficacy of orally and parenter-
ally administered curcumin was evaluated in non-obese 
diabetic̸severe combined immunodeficient (NOD/SCID) mice 
(NOD.CB17-Prkdcscid/J mice) engrafted with the human t(4;11) 
acute lymphoblastic leukemia line, SEM. SEM cells were injected 
into the tail vein and engraftment was monitored by flow cytom-
etry. Once engraftment was observed, the chemotherapeutic 
potential was examined by injecting mice intraperitoneally with 
curcumin (5 mg̸kg body weight) dissolved in dimethylsulfoxide 
(DMSO) or DMSO alone (control) every other day, or vincristine 
(0.5 mg̸kg body weight) 3 times per week for 4 weeks (n=16 
per group). The intraperitoneal administration of curcumin did 
not inhibit the growth of the leukemia cells. To determine the 
efficacy of oral curcumin, mice were fed a control diet or a diet 
containing 0.5% w/w curcumin 3 weeks prior to the injection of 
the leukemia cells and throughout the experimental period (n=16 
per group). To determine whether dietary curcumin can enhance 
the efficacy of a conventional chemotherapeutic agent, vincris-
tine was injected intraperitoneally into leukemic mice fed the 
different diets. Dietary curcumin did not delay the engraftment 
or growth of leukemia cells, or sensitize the cells to vincristine. 
Liquid chromatography-tandem mass spectrometry analyses 
of mouse sera showed that curcumin rapidly metabolized to 
glucuronidated and sulfated forms within 1 h post-injection and 
these were the major curcumin metabolites found in the sera 
of the mice fed the curcumin diet. In contrast to the findings in 
previous in vitro models, the current data indicate that orally or 
parenterally administered curcumin is not a potent preventive 
agent against high-risk t(4;11) acute lymphoblastic leukemia.
Introduction
Curcumin [1,7-bis(4-hydroxy-3-methoxyphenyl)-1E,6E-hepta-
diene-3,5-dione] is a bioactive polyphenol found in turmeric 
(Curcuma longa). Curcumin has been reported to inhibit the 
activity of a variety of signaling enzymes in cells, such as 
NF-κB, mitogen-activated protein kinases, cyclooxygenase-1, 
Bcl-2, Bcl-xL and cyclin D1, that contribute to cellular survival 
and proliferation (reviewed in refs. 1-3). Given the above effects 
of curcumin, it has been widely touted as a potential anti-carci-
nogenic agent and its efficacy has been investigated in numerous 
clinical trials (reviewed in ref. 3). While the interest in curcumin 
as a potential anti-carcinogenic agent is understandable, it is 
important to note that many of the putative anti-cancer activities 
of this phytochemical are based on data obtained from in vitro 
studies using supra-physiological concentrations of the parent 
compound. However, in vivo, curcumin undergoes rapid and 
extensive metabolic transformations that largely results in circu-
lating glucuronidated and sulfated curcumin or tetrahydro- and 
hexahydrocurcumin metabolites that have poorly documented 
functions (4,5). Therefore, the physiological significance of 
the in vitro investigations in which the parent compound was 
used may be questioned. With the above noted, several animal 
studies have suggested a potential role for curcumin in the 
prevention of select cancers. Curcumin has been reported to 
effectively suppress tumor initiation by benzo[a]pyrene and 
7,12-dimethyl-benz[a]anthracene and inhibit tumor promo-
tion induced by phorbol ester in mice (6,7). Similarly, dietary 
curcumin has been reported to have potent chemopreventive 
activity by suppressing the development of stomach and colon 
cancers (8), radiation-induced mammary tumors (9,10) and 
hepatocarcinogenesis (11) in animal models. Dietary curcumin 
has been reported to inhibit the metastasis of human breast 
cancer to the lung in immunodeficient mice (12,13). Curcumin 
administered orally at 100 and 20 mg̸kg body weight has been 
reported to increase the survival of Balb̸c mice with erythroleu-
kemia induced by infection with Friend murine leukemia virus 
Oral or parenteral administration of curcumin does not 
prevent the growth of high-risk t(4;11) acute lymphoblastic 
leukemia cells engrafted into a NOD/SCID mouse model
SUSAN J. ZUNINO1,  DAVID H. STORMS1,  JOHN W. NEWMAN1,   
THERESA L. PEDERSEN1,  CARL L. KEEN2  and  JONATHAN M. DUCORE3
1United States Department of Agriculture, Agricultural Research Service, Western Human Nutrition Research Center; 
 2Department of Nutrition, University of California Davis, Davis, CA 95616; 3Department of Pediatrics, 
 Section of Hematology/Oncology, University of California School of Medicine, Sacramento, CA 95817, USA
Received September 27, 2012;  Accepted November 16, 2012
DOI: 10.3892/ijo.2012.1734
Correspondence to: Dr Susan J. Zunino, Western Human Nutrition 
Research Center, 430 West Health Sciences Drive, Davis, CA 95616, 
USA
E-mail: susan.zunino@ars.usda.gov
Key words: acute lymphoblastic leukemia, curcumin, non-obese 
diabetic̸severe combined immunodeficient mice
ZUNINO et al:  CURCUMIN DOES NOT KILL LEUKEMIA CELLS IN MICE742
and to decrease the leukemia cell infiltration of the spleen (14). 
Daily intraperitoneal (i.p.) injections of curcumin at a concen-
tration of 40 mg̸kg body weight have been shown to lead to an 
increase in the survival of Balb̸c mice engrafted with B-acute 
lymphoblastic leukemia, although survival was only increased 
by 11 days compared to the control mice (15).
In the current study, we investigated the in vivo efficacy 
of orally and parenterally administered curcumin against a 
high-risk acute lymphoblastic leukemia (ALL) cell line with 
the chromosomal translocation t(4;11). The t(4;11) translocation 
is found in 60-80% of infants with ALL and this high-risk 
leukemia has a poor prognosis (16,17). The SEM line was estab-
lished from a relapsed patient with t(4;11) ALL (18) and used in 
our experiments to engraft non-obese diabetic̸severe combined 
immunodeficient (NOD̸SCID) mice. The ability of dietary 
or i.p. administered curcumin to reduce or prevent leukemia 
cell growth, sensitize the leukemia cells to the chemothera-
peutic agent, vincristine, or delay engraftment in these mice 
was evaluated. Serum concentrations of curcumin, curcumin 
glucuronide and curcumin sulfate were analyzed in a subset of 
mice orally or i.p. administered curcumin to determine whether 
sufficient levels of curcumin were present to prevent leukemia 
cell growth in this mouse model.
Materials and methods
Cells and reagents. The SEM cell line containing the t(4;11) 
translocation (18) was grown in RPMI-1640 (Invitrogen Life 
Technologies, Carlsbad, CA) supplemented with 10% fetal 
bovine serum (Sigma-Aldrich, St. Louis, MO), 1 mmol̸l 
sodium pyruvate, 2 mmol̸l L-glutamine, 50 IU̸ml penicillin, 
50 µg̸ml streptomycin, 0.25 µg̸ml amphotericin B (Invitrogen 
Life Technologies) and incubated at 37˚C with 5% CO2. SEM 
cells were washed twice in Dulbecco's phosphate-buffered 
saline (PBS) without Ca2+ or Mg+ (Sigma-Aldrich) and resus-
pended in PBS at a final concentration of 50x106 cells̸ml 
before injection.
Vincristine sulfate was purchased from Sigma-Aldrich 
and dissolved in PBS. For injection studies, curcumin (>98% 
pure) was purchased from Axxora LLC (San Diego, CA) and 
dissolved in dimethylsulfoxide (DMSO; Sigma-Aldrich). The 
solutions were filter-sterilized, aliquoted and frozen at -20˚C 
until use. For the feeding experiment, curcumin (>90% pure) 
was purchased in bulk from Cayman Chemical Co. (Ann Arbor, 
MI). Phycoerythrin-cyanine 7 (PE-Cy7)-conjugated anti-
human CD19 and allophycocyanin-Cy7 (APC-Cy7)-conjugated 
anti-mouse CD45 antibodies were purchased from Becton- 
Dickinson (San Jose, CA). For mass spectrometric (MS) 
analyses, the following reagents were purchased: dimethoxyc-
urcumin and 1-cyclohexyluriedo-3-dodecanoic acid (CUDA) 
(Cayman Chemical Co.), sulfatase from Aerobacter aerogenes, 
β-glucuronidase (Type IX-A) from Escherichia coli, formic 
acid, glycerol, potassium 4-nitrophenyl sulfate and 4-nitrophenyl 
β-D-glucuronide (Sigma-Aldrich), ammonium hydroxide, 
LC-MS grades of methanol, acetonitrile and water (Fisher 
Scientific Co. LLC, Fair Lawn, NJ). Normal mouse serum was 
obtained from United States Biological (Swampscott, MA).
Mice. All experimental procedures using mice were approved 
by the University of California Davis Institutional Animal 
Care and Use Committee. Female NOD.CB17-Prkdcscid̸J mice 
(5-6 weeks old) were purchased from Jackson Laboratory 
(Bar Harbor, ME; common name, NOD̸SCID mice) and 
housed in ventilator racks under pathogen-free conditions at 
the University of California, Davis Vivarium. The mice were 
maintained in a temperature-controlled environment with a 
12-h light-dark cycle and provided with sterilized food and 
water ad libitum. The addition of sterile food and water and 
cage changes were performed in a laminar flow change-out 
cabinet. Mice were weighed once per week. The weighing of 
mice and injections of leukemia cells or chemotherapeutic 
agents were performed in a biosafety cabinet to reduce the risk 
of exposure of the animals to pathogens. Mice were euthanized 
by carbon dioxide asphyxiation when they became ill or at the 
end of the experimental period.
Diets. Rodent Diet 7013 (Harlan Teklad, Madison, WI), a 
commercial NIH-31 modified diet, was used as the base diet 
for all experiments, as it is similar in composition to the diet 
used by Jackson Laboratory for the maintenance of NOD.
CB17-Prkdcscid̸J mice. For the feeding experiment, 2 interven-
tion diets were prepared by Harlan Teklad. Diet 1 was the base 
diet (control) and diet 2 was the base diet containing 0.5% w/w 
curcumin. A dietary concentration of 0.5% w/w curcumin 
is equivalent to approximately 750 mg̸kg body weight̸day 
assuming a 20-g mouse and consumption of 3 g of food̸day. 
The food was γ-irradiated for sterilization purposes. The 
pelleted food was packaged in 2-kg vacuum sealed bags to 
reduce exposure to air. Diets were stored at -20˚C until use and 
the mice were provided with fresh food weekly.
Detection of engraftment of the leukemia cells. At the age 
of 8 weeks, each mouse was injected with 5x106 SEM cells 
through the tail vein using a 1 cc syringe with a 30 gauge 
needle (Becton-Dickinson). The injection volume was 100 µl. 
The engraftment of the leukemia cells was monitored by 
the detection of human leukemic cells in the blood using a 
FACSCanto™ fluorescence-activated cell sorter (FACS) and 
FACSDiva™ software (Becton-Dickinson), as described previ-
ously (19). A total of 30,000 events were collected for each 
sample. Positive engraftment was established when the propor-
tion of human CD19+ cells reached 1% in the murine peripheral 
blood leukocyte (PBL) population (20,21).
Parenteral administration of curcumin. For i.p. injection, an 
initial dose of 100 mg curcumin̸kg body weight was used as 
this dose has been reported to be well-tolerated in rats (22). 
However, this i.p. dose increased the rate of death in the 
leukemic mice compared to the leukemic control group. 
Therefore, a dose response analysis was performed using 5, 10, 
25 and 50 mg curcumin̸kg body weight to determine the appro-
priate concentration to use in our subsequent experiments (n=4 
mice per group). A dose of 5 mg curcumin̸kg body weight was 
determined to be a safe dose in these mice. Mice (8 weeks old) 
were injected with SEM leukemia cells as described above and 
randomly separated into the control, curcumin, or vincristine 
treatment groups (n=16 per group). Once engraftment of the 
leukemia cells was established, the mice were injected i.p. every 
other day with DMSO or curcumin (5 mg̸kg body weight), or 
3 times per week with vincristine (0.5 mg̸kg body weight) for 
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a total of 4 weeks. The volumes of DMSO and curcumin were 
40-60 µl per mouse and 80-130 µl of vincristine per mouse. 
Body weights were measured weekly and the volumes of DMSO 
and therapeutic agents were adjusted accordingly. Blood from 
each mouse was monitored for the percentage of human CD19+ 
leukemia cells by flow cytometry. The mice were monitored 
daily for signs of overt illness.
Dietary intervention with curcumin. To determine whether 
dietary curcumin delays the engraftment and growth of 
leukemia cells, 32 5-week-old mice were randomly divided into 
groups and fed the control diet or the diet containing 0.5% w̸w 
curcumin (n=16 per group). After 3 weeks on the control or 
curcumin diet, each mouse (8 weeks of age) was injected with 
5x106 SEM cells and monitored for engraftment as described 
above. To determine whether dietary curcumin can enhance the 
activity of a conventional chemotherapeutic drug, all mice were 
injected i.p. with vincristine (0.5 mg̸kg body weight) 3 times 
per week. The injection of vincristine began approximately 
4.5 weeks after the injection of the leukemia cells and positive 
engraftment was well established. The total volume for each 
injection of vincristine was approximately 100 µl and was 
adjusted weekly according to the body weight of each mouse. 
All animals were maintained on the control or curcumin diets 
during the chemotherapeutic treatment and the percentage of 
human leukemia cells was monitored in the mouse blood by 
flow cytometry as described above.
Quantification of curcumin and curcumin metabolites. Blood 
from NOD̸SCID mice was collected at the end of the experi-
mental period from survivors and serum was prepared and 
frozen until use. Serum samples were thawed on ice and sepa-
rated into 25 µl aliquots for mock, glucuronidase and sulfatase 
digestions. A total of 5 µl of a 0.2 mg̸ml ethylenediaminetet-
raacetic acid and butylated hydroxytoluene was added to each 
aliquot prior to the addition of dimethoxycurcumin at 2 µmol̸l 
(recovery surrogate) and 500 nmol̸l each of nitrophenyl 
glucuronide and nitrophenyl sulfate (digestion surrogates). As 
further recovery and digestion controls, 3 aliquots of normal 
mouse serum were spiked with curcumin at 200 nmol̸l and 
the above surrogates. Digestions were performed with either 
5 µl 0.1 mmol̸l ammonium formate pH 6.9 (mock digest), 5 µl 
(0.5 kU) β-glucuronidase reconstituted in formate buffer, or 
10 µl sulfatase (0.11 U), and incubated at 37˚C in the dark for 
1 h in a shaking water bath. The serum digests were diluted 
with 75 µl water and extracted twice with 400 µl aliquots of 
cold ethyl acetate and once with 400 µl cold acetonitrile. Each 
extraction step involved a 5-min 4˚C vortex and a 10-min 4˚C 
centrifugation at 14,000 x g. The organic phases were pooled 
in a screwcap polypropylene tube containing 5 µl 50% metha-
nolic glycerol and dried using a Savant SV110A SpeedVac 
(Savant Instruments Inc., Holbrook, NY). The dried extracts 
were reconstituted in 100 µl of 100 nmol̸l CUDA (internal 
standard prepared in methanol) by vortexing and then filtered 
through 0.1 µm Amicon Ultrafree-MC durapore PVDF filters 
(Millipore, Billerica, MA) for 4 min at 4,000 x g prior to transfer 
to a glass insert in 2-ml amber vials for liquid chromatography 
(LC)-MS̸MS analysis. To assess matrix-dependent effects 
on analyte ionization, normalization solutions were prepared 
in triplicate for each batch of samples by enriching extracts 
of mock-digested normal mouse serum with target analytes 
immediately before filtration. Matrix effects on ionization were 
assessed relative to triplicate normalization solutions prepared 
in methanol containing 100 nmol̸l CUDA.
An Acquity ultra performance liquid chromatograph 
(UPLC) (Waters Corp., Milford, MA) with an Acquity BEH C18 
column (2x150 mm, 1.7 µm particle size) held at 50˚C was used 
to separate the analytes. A multistep gradient was run at a flow 
rate of 0.25 ml̸min from 90% acidified water (0.1% formic acid) 
to neat acetonitrile over 13.5 min. Samples were maintained at 
10˚C within the autosampler during each sample batch and 10 µl 
injections were made in partial loop with needle overfill mode. 
Mass spectral analysis of the UPLC effluent was performed 
with an API 4000 QTrap tandem mass spectrometer (AB Sciex, 
Foster City, CA) run in multi-reaction monitoring (MRM) mode. 
Residues were ionized using negative electrospray ionization 
(ESI-) for the first 7.75 min and positive electrospray ioniza-
tion (ESI+) for the remainder of the run. Ionization and source 
parameters for the QTrap were: heater and source temperatures, 
500˚C; curtain gas flow, 40 ml̸min; Gas 1̸Gas 2, 40 ml̸min; 
collision gas, high; ionspray voltage, 4.5 kV; and entrance 
potential (EP)̸collision cell exit potential (CXP), 10 V. The limit 
of detection of curcumin was determined from visually defined 
peaks with a signal-to-noise ratio >2 (23). The optimized analyte 
parameters used in this study are summarized in Table I.
The quantification of curcumin was accomplished with 
a 7 point standard curve ranging from 1 to 3,000 nmol̸l of 
curcumin, nitrophenyl sulfate and nitrophenyl glucuronide in 
Table I. Parameters for tandem mass spectrometric analysis of curcumin in mouse serum.a
Analyte Precursor Product + DCP + CE Retention Spiked normal
(in order of elution) (m/z) (m/z) (V) (V) time (min) serum (µM)
4-Nitrophenyl β-D-glucuronide 314.2 138.2 -50 -30 5.07 0.5
4-Nitrophenyl sulfate 218.2 138.2 -50 -30 5.71 0.5
Curcumin 369.4 177.1 +50 +30 9.19 0.2
CUDA 341.4 216.2 +58 +25 9.62 n/a
Dimethoxycurcumin 397.4 313.1 +25 +20 10.31 2.0
aAPI 4000 QTrap MS/MS parameters: ionspray voltage, 4.5 kV; curtain gas flow, 40 ml̸min; collision gas, high; heater and source tempera-
tures, 500˚C; EP̸CXP, 10 V; Gas 1̸Gas 2, 40 ml̸min. DCP, direct current plasma; CE, capillary electrophoresis.
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methanol containing 100 nmol̸l CUDA and 2 µmol̸l dime-
thoxycurcumin. Analyst 1.4.2 (AB Sciex) was used to integrate 
peak areas. Analyte signals were measured as peak area ratios 
to the internal standard, CUDA, to correct for evaporation and 
injection volume variability. A 1̸x weighted linear regres-
sion of the standard curve was used to calculate the observed 
serum curcumin level, which was corrected for losses during 
digestion and extraction and effects of the matrix on ionization 
by dividing by the fraction of the dimethoxycurcumin signal 
recovered from each sample. The matrix and methanol normal-
ization solutions were compared to distinguish matrix effects 
from extraction losses of the analytes.
Statistical analysis. GraphPad software (GraphPad Software, 
Inc., San Diego, CA) was used for statistical analyses. For the 
parenteral administration of curcumin, the event-free survival 
(EFS) was calculated beginning with the initiation of i.p. treat-
ment. For the dietary supplementation experiment, the EFS was 
calculated beginning with the day of injection of the leukemia 
cells. An event was defined as overt clinical illness that required 
euthanasia and included evidence of >20% weight loss, severe 
weakness or lethargy, or inability to reach food or water. The 
EFS was displayed as Kaplan-Meier plots with differences 
calculated using the log-rank test. Two-way analysis of vari-
ance (ANOVA) was used to compare the percentage of CD19+ 
cells between the groups over time. Data are displayed as arith-
metic means ± standard deviation. Differences were considered 
significant at α (P-value) <0.05.
Results
Intraperitoneal injections of curcumin. A 100% engraftment 
of leukemia cells was observed in the mice receiving i.p. treat-
ments of the vehicle (DMSO), curcumin, or vincristine. The 
100 mg̸kg i.p. dose of curcumin used initially in this study 
was toxic to the mice and reduced survival compared to the 
control group (Fig. 1A). Therefore, a dose-response analysis 
was performed to determine an appropriate dose for these mice. 
Doses of 5, 10, 25 and 50 mg̸kg body weight were tested (n=4 
mice per group). The 25- and 50-mg̸kg i.p. dose showed toxicity 
and the presence of a curcumin precipitate in the abdominal 
cavity. The i.p. dose of 5 mg̸kg body weight was chosen for the 
chemotherapeutic experiment as it showed no signs of toxicity 
and it was absorbed well with no signs of abdominal precipi-
tation. At 5 mg̸kg body weight, curcumin did not inhibit the 
growth of the engrafted leukemia cells compared to the control 
group, whereas vincristine treatment increased the survival of 
the mice (Fig. 1B). The body weights of the mice did not differ 
between the 2 groups (data not shown). The survival data for the 
control and vincristine groups in Fig. 1 were used previously in 
a parallel analysis of resveratrol treatment (19).
Dietary curcumin. Dietary curcumin was evaluated for its 
potential to delay engraftment and sensitize leukemia cells 
to the chemotherapeutic agent, vincristine. All 16 mice in the 
control group were engrafted with leukemia cells. A total of 
3 of the 16 mice in the group fed curcumin were not engrafted 
with the leukemia cells due to an inefficient tail vein injection 
of cells and these 3 mice were eliminated from the analyses. 
The mice were fed the intervention diets beginning at 5 weeks 
of age and the mice were injected with leukemia cells at the 
age of 8 weeks. There was no delay in engraftment of the 
leukemia cells in the mice fed curcumin compared to the 
mice fed the control diet (Fig. 2). Both groups showed similar 
percentages of human CD19+ leukemia cells at each weekly 
time-point. The mice fed the control and curcumin diets were 
injected i.p. with vincristine after engraftment was established 
to determine whether dietary curcumin enhances the efficacy 
of this chemotherapeutic agent. The arrow in Fig. 2 indicates 
the beginning of vincristine treatment. Although there was 
a drop in the percentage of human CD19+ leukemia cells in 
both groups of mice in response to vincristine, Fig. 2 shows 
that dietary curcumin did not enhance the vincristine-mediated 
reduction of leukemia cell burden. Both the control group and 
the curcumin-fed groups showed similar concentrations of 
human CD19+ leukemia cells in the mouse PBL population. 
The survival curve for the mice fed curcumin and control chow 
is shown in Fig. 3. Survival rates were similar in the 2 dietary 
groups. Body weights did not differ between the 2 groups (data 
not shown). The data for the control group in Figs. 2 and 3 were 
used previously in a parallel analysis of dietary resveratrol 
treatments (24).
Figure 1. Intraperitoneally (i.p.) administered curcumin did not prolong survival 
in NOD̸SCID mice engrafted with leukemia cells. (A) Mice were engrafted with 
the SEM cell line and treated i.p. with DMSO (n=13) or 100 mg curcumin̸kg 
body weight (n=14) every other day, or 0.5 mg vincristine̸kg body weight 
(n=13) once per week. A significant reduction in survival was observed for the 
curcumin-treated mice compared to the DMSO control and vincristine-treated 
groups (*P<0.0001). (B) Mice were engrafted with SEM cells and treated i.p. 
with DMSO or curcumin (5 mg̸kg body weight) every other day, or vincristine 
(0.5 mg̸kg body weight) 3 times per week for 4 weeks (n=16 per treatment 
group). Mice were euthanized when they showed >20% weight loss, leth-
argy, weakness, or inability to reach food or water. The vincristine-treated 
group showed an increased survival compared to both the DMSO- and cur-
cumin-treatment groups (*P<0.0001). No differences in survival were observed 
between the DMSO- and curcumin-treated mice (P=0.41). The log-rank test 
was used to determine differences in survival between the different groups 
of mice. The survival data for the control and vincristine groups were used 
previously in a parallel analysis of resveratrol treatment (19).
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Bioavailability of curcumin. The bioavailability of curcumin 
after i.p. injection and dietary intervention were determined 
in a subset of surviving mice using tandem MS. The limit of 
detection for curcumin was estimated at 0.8 nmol̸l in serum. 
Fig. 4 shows representative profiles of curcumin peaks after 
mock, glucuronidase and sulfatase digestions of mouse serum 
from the i.p. and dietary interventions, respectively. The 
deconjugation efficiency of the glucuronidase and sulfatase 
was >99% for all samples, as determined by the digestion 
surrogates, 4-nitrophenyl β-D-glucuronide and 4-nitrophenyl 
sulfate. Glucuronidase and sulfatase treatments resulted in 
increased peak intensities for curcumin in both profiles. The 
largest change in peak intensity for curcumin was observed 
after glucuronidase digestion, indicating that the majority 
of the circulating curcumin was in the form of glucuronide 
metabolites. Estimations of the amounts of curcumin aglycone 
and its metabolites were performed by measuring areas under 
the peak curves. Fig. 5 shows the approximate concentra-
tions of circulating aglycone, glucuronidated and sulfated 
metabolites in the sera after i.p. injection (Fig. 5A) and dietary 
supplementation (Fig. 5B). For the i.p. injections, serum was 
prepared from mice 1 and 48 h post-injection (Fig. 5A) and 
show that curcumin and its glucuronidated metabolites, 
although still present at low nmol̸l concentrations, were 
substantially reduced after 48 h. Serum samples were prepared 
from the euthanized mice at approximately the same time in 
the morning (roughly 10:00 am) for both the i.p. and feeding 
experiments. The mean concentration of curcumin glucuronide 
in the sera reached approximately 1.2 µmol/l at 1 h post-i.p. 
injection and 1.7 µmol̸l for the dietary intervention.
Figure 3. Dietary curcumin did not increase the survival of NOD̸SCID 
mice with t(4;11) leukemia. The mice were fed the control diet or a diet 
supplemented with 0.5% curcumin w/w 3 weeks prior to the injection of 
the SEM leukemia cells (n=16 per dietary group). Vincristine treatment was 
commenced approximately 28-30 days after the injection of the leukemia 
cells. Mice were euthanized when they showed >20% weight loss, lethargy, 
weakness, or inability to reach food or water. Three of the mice in the dietary 
curcumin group were not engrafted and were eliminated from the analysis. 
The log-rank test was used to determine differences in survival between the 
dietary groups. No differences in survival were observed between the control 
and curcumin fed mice (P=0.53). The data for the control group was used 
previously in a parallel analysis of dietary resveratrol treatments (24).
Figure 2. The percentage of human CD19+ cells in the mouse peripheral blood 
leukocyte (PBL) population was similar over time between the mice receiving 
control or curcumin diets. Mice (n=16 per group) were fed the control diet 
or a diet containing 0.5% w̸w curcumin beginning at the age of 5 weeks. 
The mice were injected with SEM cells through the tail vein at 8 weeks of 
age. Two weeks after injection of leukemia cells, the PBLs were isolated from 
each mouse weekly and stained with PE-Cy7-conjugated anti-human CD19 
and APC-Cy7-conjugated anti-mouse CD45 antibodies to monitor engraft-
ment and growth by flow cytometry. Engraftment was monitored weekly. 
Three of the mice in the dietary curcumin group were not engrafted and were 
eliminated from the analysis. The arrow indicates the beginning of vincris-
tine treatment. No difference in the percentage of CD19+ cells was observed 
between the 2 dietary groups. Data represent the means ± SD. The data for the 
control group was used previously in a parallel analysis of dietary resveratrol 
treatments (24).
Figure 4. Liquid chromatography (LC)-tandem mass spectrometry (MS)
profiles of curcumin from mouse serum after deconjugation of metabolites. 
(A) Serum samples were collected from 5 surviving mice 1 h after i.p. injec-
tion with curcumin and digested with buffer (mock), β-glucuronidase, or 
sulfatase. The profile shows the representative results from 1 mouse. Ultra-
performance LC (UPLC)-MS̸MS chromatograms show increased peak 
areas for curcumin after deconjugation with β-glucuronidase or sulfatase 
compared to the mock digestion, most notably with the glucuronidase diges-
tion. (B) Serum samples were collected from 5 surviving mice that received 
diet supplemented with 0.5% w̸w curcumin and digested with buffer (mock), 
β-glucuronidase, or sulfatase. The profile shows the representative results 
from 1 mouse. UPLC-MS̸MS chromatograms show increased peak areas for 
curcumin after deconjugation with β-glucuronidase or sulfatase compared to 
the mock digestion.
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Discussion
Both orally and i.p. administered curcumin were evaluated as 
effective modes of preventing the growth of t(4;11) ALL cells 
in the NOD̸SCID mouse leukemia model. Human feeding 
studies have shown that dietary curcumin up to 10 g is well 
tolerated, with minimal side-effects noted, such as mild diar-
rhea and headaches (25-27). In the current study, the estimated 
daily dose of curcumin in the mouse diet was 750 mg̸kg body 
weight, which is equivalent to approximately 52 g of curcumin 
for a 70-kg human per day, based on body weight. No adverse 
effects were observed in the leukemic mice fed this amount of 
curcumin in their diet. However, this level of dietary curcumin 
did not decrease the engraftment and growth of leukemia cells 
in these animals. It should be noted that 3 mice in the dietary 
curcumin group were not engrafted with leukemia cells and 
were not included in the analysis of the dietary intervention. 
Although 100% engraftment was achieved in the other experi-
mental groups described in this study, the lack of engraftment 
of these 3 mice was likely due to error in the tail vein injections 
and not to the dietary curcumin. This is supported by the data 
from the other 13 mice in the curcumin group who displayed 
the typical rapid growth of the SEM leukemia cells with no 
differences in survival or percentage of CD19+ cells compared 
to the control group.
While an i.p. dose of curcumin at 100 mg̸kg body weight has 
been administered to rats in previous studies (22), we observed 
this amount of curcumin to be toxic to NOD̸SCID mice 
engrafted with the t(4;11) ALL cell line, SEM. This observation 
resulted in a substantial reduction of the i.p. dose of curcumin 
that we subsequently administered to the mice in our study. 
Similarly, the NOD̸SCID mice engrafted with the leukemia 
cells in our previous study were unable to tolerate high doses of 
i.p. injected resveratrol (19). For the i.p. curcumin administra-
tion, we observed the presence of an orange precipitate in the 
abdominal cavity at doses of 25 and 50 mg curcumin̸kg body 
weight, indicating that curcumin was not absorbed efficiently 
at high concentrations in these mice. Other investigators have 
used a dose of 40 mg curcumin̸kg body weight in Balb̸c mice 
to treat ALL with an injection volume of 200 µl (15). These 
investigators did not report toxicity or abdominal precipitates 
in their mice. However, the NOD̸SCID mice were sensitive 
to DMSO at injection volumes of 100 µl or more, showing 
temporary hindlimb paralysis (19). To alleviate the neuro-
logical sensitivity, we reduced the injection volume of DMSO 
to 40-60 µl. A different vehicle that was more tolerable to the 
NOD̸SCID mice may have allowed a greater injection volume 
and administration of higher concentrations of curcumin than 
reported in this study. At the i.p. dose of 5 mg curcumin̸kg 
body weight, curcumin did not show any evidence of growth 
inhibition of t(4;11) ALL cells.
Pharmacokinetic studies have been performed using 
animals and humans to assess the bioavailability of curcumin 
and its metabolites following absorption. The tissue distribu-
tion and excretion of 3H-labelled curcumin has been evaluated 
in rats (28). While the majority of dietary curcumin is elimi-
nated in the feces, 12 days after a single oral dose of 400 mg 
curcumin̸kg body weight, approximately 13% of the radio-
activity remained in the blood, 5% in the liver and 0.45% in 
the kidneys. In mice, a single i.p. dose of 100 mg curcumin̸kg 
body weight resulted in approximately 177, 26, 27 and 8 µg 
of curcumin̸g of tissue in the intestines, spleen, liver and 
kidneys, respectively, 1 h post-injection (4). The total amount of 
curcumin per organ was calculated as 319.52 µg in the intestine, 
2.61 µg in the spleen, 33.09 µg in the liver and 3 µg in the 
kidneys. The evaluation of the metabolites of curcumin from 
the plasma revealed the presence of glucuronide conjugates in 
this study. In humans, blood levels have been reported to peak 
at approximately 1.8 µmol̸l in the serum of individuals 2 h after 
consuming 8 g curcumin (29). Other studies have detected both 
glucuronidated and sulfated forms of curcumin in the plasma 
of humans after oral administration (25). Vareed et al (30) 
detected a maximum of approximately 2 mg̸l of curcumin 
glucuronide and 1 mg̸l curcumin sulfate in human plasma 
after consumption of a single dose of 10 g curcumin. These 
authors found that the glucuronidated and sulfated metabolites 
were almost exclusively present in the plasma with little or no 
detectable curcumin aglycone. In the current study, curcumin 
glucuronide and sulfate were the major curcumin metabolites 
found in mice after i.p. and dietary treatments, which concurs 
with the data from the studies mentioned above.
Curcumin has been reported to exert cancer-preventive 
activities, most notably in animal studies of epithelial-derived 
cancers, such as colon, skin and stomach cancers (6-8), where 
the unmetabolized aglycone of this molecule would be 
more accessible to cancerous epithelial cells and present at 
its highest level. Importantly, the majority of recent clinical 
trials using curcumin have focused on oral and gastrointes-
Figure 5. Curcumin glucuronide is the major form of curcumin in leukemic 
mice. (A) Mice were intraperitoneally (i.p.) injected with curcumin and the 
sera were collected at 1 and 48 h post-injection (n=5 for each time-point). The 
serum samples were analyzed by ultra-performance liquid chromatography 
(UPLC)-mass spectometry (MS)̸MS after digestion with buffer (mock), gluc-
uronidase and sulfatase. The concentrations of curcumin and its metabolites 
were estimated from the areas under the curves of the resulting curcumin 
peaks after the digestion. (B) Serum samples were collected from mice fed 
chow supplemented with 0.5% curcumin (n=5) and digested with buffer 
(mock), glucuronidase and sulfatase. The samples were analyzed as above and 
the concentrations of curcumin and its metabolites were estimated from the 
areas under the curves of the curcumin peaks after digestion. Data represent 
the means ± SD.
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tinal cancers (3). A Phase IIa clinical trial for the prevention 
of colorectal neoplasia by oral curcumin was performed 
using 2- and 4-g doses of curcumin in 41 subjects with aber-
rant crypt foci (31). The authors reported that curcumin at 
an oral dose of 4 g̸day for 30 days produced a 40% redu-
ction in aberrant crypt foci. In another human study, dietary 
curcumin significantly reduced the relapse of ulcerative 
colitis, a perceived precursor to colon cancer, during a 
6-month co-treatment with sulfasalazine or mesalamine (32). 
Curcumin has been evaluated as a potential treatment for 
pancreatic cancer in humans with limited results (33). A total 
of 2 out of 21 evaluable patients had a biological response to 
8 g̸day of orally administered curcumin. These 2 patients 
displayed stabilization of disease or marked, but brief, tumor 
regression. The authors attributed the lack of responsiveness 
to the low bioavailability of curcumin.
There has been considerable interest in developing novel 
delivery systems to increase the bioavailability of absorbed 
curcumin. Delivery systems include nanoparticles, nanogels, 
liposomes and nanocrystals (reviewed in ref. 34). Poly(lactic-
co-glycolic acid) nanoparticles of curcumin showed a 5.6-fold 
greater bioavailability and longer half-life than native curcumin 
in rats (35). Nano-emulsions of curcumin with polyethylene 
glycol and the castor oil derivative, Cremaphor EL®, increased 
the maximum concentration of curcumin 40-fold in mice (36). 
Curcumin has been reported to chemosensitize a number of 
different cancers to the activities of standard chemotherapeutic 
drugs (37). Liposomally encapsulated curcumin at a concen-
tration of 25 mg̸kg body weight synergized with paclitaxel 
to reduce cervical tumor incidence and volume in mice (38). 
Oil-in-water nanoemulsions of curcumin combined with pacli-
taxel have been shown to significantly reduce tumor volume 
in mice bearing subcutaneous ovarian adenocarcinoma by 
delaying the proliferation and growth of the tumor cells (39).
At the concentrations described in this study, curcumin, 
whether injected or fed, failed to reduce the growth of the SEM 
leukemia cells in the NOD̸SCID mouse model. The SEM 
leukemia line was derived from a patient with relapsed t(4;11) 
ALL, indicating that these cells had gone through chemothera-
peutic selection processes resulting in chemotherapy resistance. 
We have shown that these SEM leukemia cells underwent a 
rapid reversion to a chemotherapy-resistant phenotype in 
NOD̸SCID mice when challenged with vincristine, which is a 
standard chemotherapeutic agent used in the treatment of this 
disease (40,41). It is still a possibility that curcumin may be 
effective against t(4;11) ALL at the time of diagnosis before 
resistance mechanisms are enhanced and the analysis of the 
efficacy of curcumin against t(4;11) ALL needs to be further 
examined. Curcumin may also prove to be effective against less 
aggressive forms of ALL. However, further evaluation of this 
agent should take into account the rapid metabolic transforma-
tion of curcumin that occurs in vivo and the generation of a 
unique delivery system plus the use of a combinatorial chemo-
therapeutic approach will likely be required for the effective 
treatment of this disease.
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